Selvaraj Chandrabose, Sivakamavalli Jeyachandran, Baskaralingam Vaseeharan, Singh Sanjeev Kumar
Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University , Karaikudi, Tamil Nadu , India and.
J Recept Signal Transduct Res. 2014 Jun;34(3):221-32. doi: 10.3109/10799893.2013.876044. Epub 2014 Feb 3.
Members of the sortase enzyme super family decorate the surfaces of Bacillus anthracis cell wall with proteins that play key roles in microbial pathogenesis and its biofilm formation. Bacillus anthracis Sortase-A (Ba-SrtA) is a potential target for new therapeutics as it is required for B. anthracis survival and replication within macrophages. An understanding of the binding site pocket and substrate recognition mechanism by SrtA enzymes may serve to be beneficial in the rational development of sortase inhibitors. Here, the LPXTG signal peptide-based competitive inhibitors are screened against the Ba-SrtA and compounds with reasonable inhibition, specificity, and mechanisms of inactivation of SrtA have been covered. The screened compounds are experimentally validated against the phylogenetically similar Gram-positive pathogen B. cereus. In situ microscopic visualizations suggest that these screened compounds showed the microbial and biofilm inhibitory activity against B. cereus. It facilitates the further development of these molecules into useful anti-infective agents to treat infections caused by B. anthracis and other Gram-positive pathogens. These results provide insight into basic design principles for generating new clinically relevant lead molecules. It also provides an alternative strategy where a screened ligand molecule can be used in combination to battle increasingly against the Gram-positive pathogens.
分选酶超家族的成员用在微生物发病机制及其生物膜形成中起关键作用的蛋白质修饰炭疽芽孢杆菌细胞壁的表面。炭疽芽孢杆菌分选酶-A(Ba-SrtA)是新疗法的潜在靶点,因为它是炭疽芽孢杆菌在巨噬细胞内存活和复制所必需的。了解分选酶对结合位点口袋和底物的识别机制可能有助于合理开发分选酶抑制剂。在此,针对Ba-SrtA筛选了基于LPXTG信号肽的竞争性抑制剂,并涵盖了具有合理抑制作用、特异性和SrtA失活机制的化合物。对筛选出的化合物针对系统发育相似的革兰氏阳性病原体蜡状芽孢杆菌进行了实验验证。原位显微镜观察表明,这些筛选出的化合物对蜡状芽孢杆菌具有微生物和生物膜抑制活性。这有助于将这些分子进一步开发成有用的抗感染药物,以治疗由炭疽芽孢杆菌和其他革兰氏阳性病原体引起的感染。这些结果为生成新的临床相关先导分子的基本设计原则提供了见解。它还提供了一种替代策略,即可以将筛选出的配体分子联合使用,以对抗日益增多的革兰氏阳性病原体。